Why Lexicon Pharmaceuticals Is Down 11% Today
After Lexicon Pharmaceuticals (NASDAQ: LXRX) announced yesterday the publication of phase 3 results for its lead diabetes drug, sotagliflozin, in the New England Journal of Medicine, its shares are losing 11% of their value at 11:45 a.m. EDT.
Sotagliflozin is a novel diabetes drug that attempts to improve glycemic control by targeting both SGLT1 and SGLT2 for the first time.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Sanofi S.A. ADR Stock
€37.80
0.530%
Currently there is a rather positive sentiment for Sanofi S.A. ADR with 4 Buy predictions and 0 Sell predictions.
As a result the target price of 49 € shows a positive potential of 29.63% compared to the current price of 37.8 € for Sanofi S.A. ADR.
